Recombinant erythroid differentiation regulator 1 inhibits both inflammation and angiogenesis in a mouse model of rosacea

Miri Kim, Kyung Eun Kim, Haw Young Jung, Hyunmu Jo, Seo Won Jeong, Jahyung Lee, Chang Han Kim, Heejong Kim, Dae Ho Cho, Hyun Jeong Park

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The erythroid differentiation regulator 1 (Erdr1), which is a novel and highly conserved factor, was recently reported to be negatively regulated by IL-18 and to play a crucial role as an antimetastatic factor. IL-18 is a proinflammatory cytokine that functions as an angiogenic mediator in inflammation. Rosacea is a chronic inflammatory skin disorder that is characterized by abnormal inflammation and vascular hyperactivity of the facial skin. To determine whether Erdr1 contributes to the regulation of the chronic inflammatory process in the development of rosacea, an immunohistochemical analysis was performed in healthy donors and patients with rosacea. In this study, we showed that Erdr1 was downregulated, whereas IL-18 was upregulated, in patients with rosacea, which led us to question the role of Erdr1 in this disorder. Moreover, a rosacea-like BALB/c mouse model was used to determine the role of Erdr1 in rosacea in vivo. LL-37 injection induced typical rosacea features, including erythema, telangiectasia and inflammation. Treatment with recombinant Erdr1 (rErdr1) resulted in a significant reduction of erythema, inflammatory cell infiltration (including CD4+ and CD8+ T cells), and microvessel density with vascular endothelial growth factor (VEGF). Taken together, our findings suggest that rErdr1 may be involved in attenuating the inflammation and angiogenesis associated with the pathogenesis of rosacea. Thus, these results provide new insight into the mechanism involved in this condition and indicate that rErdr1 could be a potential target for therapeutic intervention of rosacea.

Original languageEnglish
Pages (from-to)680-685
Number of pages6
JournalExperimental Dermatology
Volume24
Issue number9
DOIs
Publication statusPublished - 2015 Sep 1
Externally publishedYes

Fingerprint

Rosacea
Interleukin-18
Inflammation
Skin
T-cells
Infiltration
Vascular Endothelial Growth Factor A
Erythema
Cytokines
Inflammation Mediators
Telangiectasis
Microvessels
Blood Vessels
Down-Regulation
Cell Count
Tissue Donors
T-Lymphocytes
Injections

Keywords

  • Angiogenesis
  • Erdr1
  • IL-18
  • Inflammation
  • Rosacea

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology

Cite this

Recombinant erythroid differentiation regulator 1 inhibits both inflammation and angiogenesis in a mouse model of rosacea. / Kim, Miri; Kim, Kyung Eun; Jung, Haw Young; Jo, Hyunmu; Jeong, Seo Won; Lee, Jahyung; Kim, Chang Han; Kim, Heejong; Cho, Dae Ho; Park, Hyun Jeong.

In: Experimental Dermatology, Vol. 24, No. 9, 01.09.2015, p. 680-685.

Research output: Contribution to journalArticle

Kim, Miri ; Kim, Kyung Eun ; Jung, Haw Young ; Jo, Hyunmu ; Jeong, Seo Won ; Lee, Jahyung ; Kim, Chang Han ; Kim, Heejong ; Cho, Dae Ho ; Park, Hyun Jeong. / Recombinant erythroid differentiation regulator 1 inhibits both inflammation and angiogenesis in a mouse model of rosacea. In: Experimental Dermatology. 2015 ; Vol. 24, No. 9. pp. 680-685.
@article{046ed6b597db40b59d959c8dd4403cef,
title = "Recombinant erythroid differentiation regulator 1 inhibits both inflammation and angiogenesis in a mouse model of rosacea",
abstract = "The erythroid differentiation regulator 1 (Erdr1), which is a novel and highly conserved factor, was recently reported to be negatively regulated by IL-18 and to play a crucial role as an antimetastatic factor. IL-18 is a proinflammatory cytokine that functions as an angiogenic mediator in inflammation. Rosacea is a chronic inflammatory skin disorder that is characterized by abnormal inflammation and vascular hyperactivity of the facial skin. To determine whether Erdr1 contributes to the regulation of the chronic inflammatory process in the development of rosacea, an immunohistochemical analysis was performed in healthy donors and patients with rosacea. In this study, we showed that Erdr1 was downregulated, whereas IL-18 was upregulated, in patients with rosacea, which led us to question the role of Erdr1 in this disorder. Moreover, a rosacea-like BALB/c mouse model was used to determine the role of Erdr1 in rosacea in vivo. LL-37 injection induced typical rosacea features, including erythema, telangiectasia and inflammation. Treatment with recombinant Erdr1 (rErdr1) resulted in a significant reduction of erythema, inflammatory cell infiltration (including CD4+ and CD8+ T cells), and microvessel density with vascular endothelial growth factor (VEGF). Taken together, our findings suggest that rErdr1 may be involved in attenuating the inflammation and angiogenesis associated with the pathogenesis of rosacea. Thus, these results provide new insight into the mechanism involved in this condition and indicate that rErdr1 could be a potential target for therapeutic intervention of rosacea.",
keywords = "Angiogenesis, Erdr1, IL-18, Inflammation, Rosacea",
author = "Miri Kim and Kim, {Kyung Eun} and Jung, {Haw Young} and Hyunmu Jo and Jeong, {Seo Won} and Jahyung Lee and Kim, {Chang Han} and Heejong Kim and Cho, {Dae Ho} and Park, {Hyun Jeong}",
year = "2015",
month = "9",
day = "1",
doi = "10.1111/exd.12745",
language = "English",
volume = "24",
pages = "680--685",
journal = "Experimental Dermatology",
issn = "0906-6705",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Recombinant erythroid differentiation regulator 1 inhibits both inflammation and angiogenesis in a mouse model of rosacea

AU - Kim, Miri

AU - Kim, Kyung Eun

AU - Jung, Haw Young

AU - Jo, Hyunmu

AU - Jeong, Seo Won

AU - Lee, Jahyung

AU - Kim, Chang Han

AU - Kim, Heejong

AU - Cho, Dae Ho

AU - Park, Hyun Jeong

PY - 2015/9/1

Y1 - 2015/9/1

N2 - The erythroid differentiation regulator 1 (Erdr1), which is a novel and highly conserved factor, was recently reported to be negatively regulated by IL-18 and to play a crucial role as an antimetastatic factor. IL-18 is a proinflammatory cytokine that functions as an angiogenic mediator in inflammation. Rosacea is a chronic inflammatory skin disorder that is characterized by abnormal inflammation and vascular hyperactivity of the facial skin. To determine whether Erdr1 contributes to the regulation of the chronic inflammatory process in the development of rosacea, an immunohistochemical analysis was performed in healthy donors and patients with rosacea. In this study, we showed that Erdr1 was downregulated, whereas IL-18 was upregulated, in patients with rosacea, which led us to question the role of Erdr1 in this disorder. Moreover, a rosacea-like BALB/c mouse model was used to determine the role of Erdr1 in rosacea in vivo. LL-37 injection induced typical rosacea features, including erythema, telangiectasia and inflammation. Treatment with recombinant Erdr1 (rErdr1) resulted in a significant reduction of erythema, inflammatory cell infiltration (including CD4+ and CD8+ T cells), and microvessel density with vascular endothelial growth factor (VEGF). Taken together, our findings suggest that rErdr1 may be involved in attenuating the inflammation and angiogenesis associated with the pathogenesis of rosacea. Thus, these results provide new insight into the mechanism involved in this condition and indicate that rErdr1 could be a potential target for therapeutic intervention of rosacea.

AB - The erythroid differentiation regulator 1 (Erdr1), which is a novel and highly conserved factor, was recently reported to be negatively regulated by IL-18 and to play a crucial role as an antimetastatic factor. IL-18 is a proinflammatory cytokine that functions as an angiogenic mediator in inflammation. Rosacea is a chronic inflammatory skin disorder that is characterized by abnormal inflammation and vascular hyperactivity of the facial skin. To determine whether Erdr1 contributes to the regulation of the chronic inflammatory process in the development of rosacea, an immunohistochemical analysis was performed in healthy donors and patients with rosacea. In this study, we showed that Erdr1 was downregulated, whereas IL-18 was upregulated, in patients with rosacea, which led us to question the role of Erdr1 in this disorder. Moreover, a rosacea-like BALB/c mouse model was used to determine the role of Erdr1 in rosacea in vivo. LL-37 injection induced typical rosacea features, including erythema, telangiectasia and inflammation. Treatment with recombinant Erdr1 (rErdr1) resulted in a significant reduction of erythema, inflammatory cell infiltration (including CD4+ and CD8+ T cells), and microvessel density with vascular endothelial growth factor (VEGF). Taken together, our findings suggest that rErdr1 may be involved in attenuating the inflammation and angiogenesis associated with the pathogenesis of rosacea. Thus, these results provide new insight into the mechanism involved in this condition and indicate that rErdr1 could be a potential target for therapeutic intervention of rosacea.

KW - Angiogenesis

KW - Erdr1

KW - IL-18

KW - Inflammation

KW - Rosacea

UR - http://www.scopus.com/inward/record.url?scp=84939190152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939190152&partnerID=8YFLogxK

U2 - 10.1111/exd.12745

DO - 10.1111/exd.12745

M3 - Article

C2 - 25940661

AN - SCOPUS:84939190152

VL - 24

SP - 680

EP - 685

JO - Experimental Dermatology

JF - Experimental Dermatology

SN - 0906-6705

IS - 9

ER -